What if you invested $1000 in BMY on Jan 1, 2020?
Explore hypothetical investment results for stocks, ETFs, and more. See real historical data and share your discoveries.
Historical Annual Returns
Over the past 20 years, Bristol Myers Squibb Company has delivered an average annual return of 9.6%. The stock peaked in 2013 with a massive +67.5% gain, while investors faced a downturn in 2023 (-26.5%). Overall, the stock finished in the green 14 times out of 20 years.
Avg Return
+9.6%
Win Rate
70%
14W - 6L
Best
+67.5%
2013
Worst
-26.5%
2023
Performance Consistency
About Bristol Myers Squibb Company
Visit Website ↗Bristol Myers Squibb is a global biopharmaceutical company dedicated to discovering, developing and delivering innovative medicines that help patients prevail over serious diseases. The company focuses on areas such as oncology, hematology, immunology, and cardiovascular disease.
Key Business Segments
Oncology
Develops and commercializes medicines for various types of cancer.
Hematology
Develops and commercializes medicines for blood disorders.
Immunology
Develops and commercializes medicines for autoimmune and inflammatory diseases.
Cardiovascular
Develops and commercializes medicines for cardiovascular diseases.
Key Innovations
- ✓Pioneered the development of many life-saving medicines across a range of therapeutic areas.
- ✓A leader in oncology and immunology research and development.
Historical Milestones
Edward Robinson Squibb founds Squibb in Brooklyn, New York.
William McLaren Bristol and John Ripley Myers found Bristol, Myers and Company.
Bristol-Myers and Squibb merge to form Bristol Myers Squibb.
Bristol Myers Squibb acquires Celgene, significantly expanding its oncology and immunology portfolio.